BPMC BPMC

Blueprint Medicines Stock Price

47.79
1.19 (2.55%)
Upgrade to Real-Time
Afterhours (Closed)
47.79
Volume 614,313
Bid Price 45.80
Ask Price 58.55
News -
Day High 47.93

Low
40.78

52 Week Range

High
111.78

Day Low 45.575
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.19 2.55% 47.79 20:00:00
Open Price Low Price High Price Close Price Prev Close
47.83 45.575 47.93 47.79 46.60
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,212 614,313 $ 46.90 $ 28,813,080 - 40.78 - 111.78
Last Trade Time Type Quantity Stock Price Currency
16:27:36 priorref 1,713 $ 47.79 USD

Period:

Draw Mode:

Blueprint Medicines Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 2.86B 59.83M 59.52M $ 180.08M $ 73.98M -11.01 -3.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -48.48k 1.90%

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BPMC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week43.6747.9343.6745.62596,8184.129.43%
1 Month46.8348.3540.7843.74651,0490.962.05%
3 Months71.2379.4040.7854.53707,099-23.44-32.91%
6 Months55.8879.4040.7857.20851,200-8.09-14.48%
1 Year97.57111.7840.7863.07731,061-49.78-51.02%
3 Years81.45125.6140.7874.87595,055-33.66-41.33%
5 Years71.17125.6140.7875.53529,738-23.38-32.85%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.